Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TazCoV and Vidicine for Acute Respiratory Viral Infections
NCT05897203Phase 2Unknown
- Sponsor
- Makerere University
- Start
- Mar 2023
- Primary completion
- Jan 2024
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of TAZCOV, liposomal cytarabine in Acute Respiratory Infection (ARI), coronavirus disease 2019 (COVID-19), influenza, respiratory syncytial virus infection (RSV), sponsored by Makerere University. Status: unknown.
02
Drugs
TAZCOVliposomal cytarabine
03
Conditions
Acute Respiratory Infection (ARI)coronavirus disease 2019 (COVID-19)influenzarespiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05897203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05897203.